{"id":25131,"date":"2022-10-13T13:24:00","date_gmt":"2022-10-13T05:24:00","guid":{"rendered":"https:\/\/flcube.com\/?p=25131"},"modified":"2025-02-03T13:27:37","modified_gmt":"2025-02-03T05:27:37","slug":"beigenes-brukinsa-outperforms-imbruvica-in-phase-iii-alpine-study","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=25131","title":{"rendered":"BeiGene’s Brukinsa Outperforms Imbruvica in Phase III ALPINE Study"},"content":{"rendered":"\n

China-based biotech BeiGene Inc. (HKG: 6160<\/a>, SHA: 688235<\/a>, NASDAQ: BGNE)\u00a0 has announced that its Bruton’s tyrosine kinase (BTK) inhibitor Brukinsa (zanubrutinib) demonstrated superior progression-free survival (PFS) in the Phase III ALPINE study compared to Johnson & Johnson’s Imbruvica (ibrutinib). The 12-month PFS rate for Brukinsa was 94.9%, compared to 84% for Imbruvica. Additionally, Brukinsa was well tolerated, with safety consistent with previous reports. Previously, BeiGene reported a superior overall response rate (ORR) for Brukinsa over ibrutinib based on data from the same ALPINE study in April 2022.<\/p>\n\n\n\n

Study Design and Results<\/strong>
The randomized, global Phase III ALPINE study assessed the effects of Brukinsa compared to ibrutinib in previously treated patients with relapsed or refractory (r\/r) chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL). A total of 652 patients were enrolled in the study, with 60% from Europe, 17% from the United States, 14% from China, and 9% from New Zealand and Australia. Patients were randomly divided into two groups and treated with either Brukinsa (160mg, oral, twice daily) or ibrutinib (420mg, oral, once daily) until disease progression or unacceptable toxicity. The primary endpoint was the overall response rate (ORR), while key secondary endpoints included PFS and the incidence of atrial fibrillation or atrial flutter. Other secondary endpoints included duration of remission (DoR), overall survival (OS), and the incidence of adverse events.<\/p>\n\n\n\n

Regulatory and Market Presence<\/strong>
Brukinsa was first approved in the United States in November 2019 for the treatment of mantle cell lymphoma (MCL) in previously treated adult patients. In China, Brukinsa was approved for both MCL and for previously treated adults with CLL or SLL in June 2020. The drug is currently undergoing 35 clinical studies in 28 markets globally, targeting multiple B-cell malignant tumors either as monotherapy or in combination with other therapies.<\/p>\n\n\n\n

Competitive Landscape<\/strong>
Ibrutinib, an oral BTK inhibitor co-developed by Cilag GmbH International (a Janssen Pharmaceuticals subsidiary) and Pharmacyclics LLC (an AbbVie company), was first approved in the US in 2014 and gained market approval in China in 2017. The drug is currently available for use in CLL\/SLL, MCL, Waldenstr\u00f6m’s macroglobulinemia (WM), marginal zone lymphoma (MZL), and chronic graft versus host disease (cGVHD).<\/p>\n\n\n\n

Future Outlook<\/strong>
The superior results from the Phase III ALPINE study underscore Brukinsa’s potential as a leading BTK inhibitor. BeiGene’s commitment to advancing innovative treatments for B-cell malignancies positions the company to further expand its market presence and improve patient outcomes.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE)\u00a0 has announced that its Bruton’s…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[2092,16,17,29,847,846,848,33],"class_list":["post-25131","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-beone-medicines","tag-cancer","tag-clinical-trial-results","tag-combination-therapy","tag-hkg-6160","tag-nasdaq-bgne","tag-sha-688235","tag-tkis-egfr-vegf-btk-etc"],"yoast_head":"\nBeiGene's Brukinsa Outperforms Imbruvica in Phase III ALPINE Study - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE)\u00a0 has announced that its Bruton's tyrosine kinase (BTK) inhibitor Brukinsa (zanubrutinib) demonstrated superior progression-free survival (PFS) in the Phase III ALPINE study compared to Johnson & Johnson's Imbruvica (ibrutinib). The 12-month PFS rate for Brukinsa was 94.9%, compared to 84% for Imbruvica. Additionally, Brukinsa was well tolerated, with safety consistent with previous reports. Previously, BeiGene reported a superior overall response rate (ORR) for Brukinsa over ibrutinib based on data from the same ALPINE study in April 2022.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=25131\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BeiGene's Brukinsa Outperforms Imbruvica in Phase III ALPINE Study\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=25131\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-13T05:24:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-03T05:27:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25131#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25131\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"BeiGene’s Brukinsa Outperforms Imbruvica in Phase III ALPINE Study\",\"datePublished\":\"2022-10-13T05:24:00+00:00\",\"dateModified\":\"2025-02-03T05:27:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25131\"},\"wordCount\":404,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"BeOne Medicines\",\"Cancer\",\"Clinical trial results\",\"Combination therapy\",\"HKG: 6160\",\"NASDAQ: BGNE\",\"SHA: 688235\",\"TKIs (EGFR VEGF BTK etc.)\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=25131#respond\"]}],\"copyrightYear\":\"2022\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25131\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=25131\",\"name\":\"BeiGene's Brukinsa Outperforms Imbruvica in Phase III ALPINE Study - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2022-10-13T05:24:00+00:00\",\"dateModified\":\"2025-02-03T05:27:37+00:00\",\"description\":\"China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE)\u00a0 has announced that its Bruton's tyrosine kinase (BTK) inhibitor Brukinsa (zanubrutinib) demonstrated superior progression-free survival (PFS) in the Phase III ALPINE study compared to Johnson & Johnson's Imbruvica (ibrutinib). The 12-month PFS rate for Brukinsa was 94.9%, compared to 84% for Imbruvica. Additionally, Brukinsa was well tolerated, with safety consistent with previous reports. Previously, BeiGene reported a superior overall response rate (ORR) for Brukinsa over ibrutinib based on data from the same ALPINE study in April 2022.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25131#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=25131\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25131#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BeiGene’s Brukinsa Outperforms Imbruvica in Phase III ALPINE Study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"BeiGene's Brukinsa Outperforms Imbruvica in Phase III ALPINE Study - Insight, China's Pharmaceutical Industry","description":"China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE)\u00a0 has announced that its Bruton's tyrosine kinase (BTK) inhibitor Brukinsa (zanubrutinib) demonstrated superior progression-free survival (PFS) in the Phase III ALPINE study compared to Johnson & Johnson's Imbruvica (ibrutinib). The 12-month PFS rate for Brukinsa was 94.9%, compared to 84% for Imbruvica. Additionally, Brukinsa was well tolerated, with safety consistent with previous reports. Previously, BeiGene reported a superior overall response rate (ORR) for Brukinsa over ibrutinib based on data from the same ALPINE study in April 2022.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=25131","og_locale":"en_US","og_type":"article","og_title":"BeiGene's Brukinsa Outperforms Imbruvica in Phase III ALPINE Study","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=25131","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2022-10-13T05:24:00+00:00","article_modified_time":"2025-02-03T05:27:37+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=25131#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=25131"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"BeiGene’s Brukinsa Outperforms Imbruvica in Phase III ALPINE Study","datePublished":"2022-10-13T05:24:00+00:00","dateModified":"2025-02-03T05:27:37+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=25131"},"wordCount":404,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["BeOne Medicines","Cancer","Clinical trial results","Combination therapy","HKG: 6160","NASDAQ: BGNE","SHA: 688235","TKIs (EGFR VEGF BTK etc.)"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=25131#respond"]}],"copyrightYear":"2022","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=25131","url":"https:\/\/flcube.com\/?p=25131","name":"BeiGene's Brukinsa Outperforms Imbruvica in Phase III ALPINE Study - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2022-10-13T05:24:00+00:00","dateModified":"2025-02-03T05:27:37+00:00","description":"China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE)\u00a0 has announced that its Bruton's tyrosine kinase (BTK) inhibitor Brukinsa (zanubrutinib) demonstrated superior progression-free survival (PFS) in the Phase III ALPINE study compared to Johnson & Johnson's Imbruvica (ibrutinib). The 12-month PFS rate for Brukinsa was 94.9%, compared to 84% for Imbruvica. Additionally, Brukinsa was well tolerated, with safety consistent with previous reports. Previously, BeiGene reported a superior overall response rate (ORR) for Brukinsa over ibrutinib based on data from the same ALPINE study in April 2022.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=25131#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=25131"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=25131#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"BeiGene’s Brukinsa Outperforms Imbruvica in Phase III ALPINE Study"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/25131","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=25131"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/25131\/revisions"}],"predecessor-version":[{"id":25132,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/25131\/revisions\/25132"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=25131"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=25131"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=25131"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}